Portal de Periódicos da CAPES

Targeting RNA G‐quadruplexes as new treatment strategy for C9orf72 ALS / FTD

2017; Springer Nature; Volume: 10; Issue: 1 Linguagem: Inglês

10.15252/emmm.201708572

1757-4684

Martin H. Schludi, Dieter Edbauer,

RNA Interference and Gene Delivery

News & Views24 November 2017Open Access Targeting RNA G-quadruplexes as new treatment strategy for C9orf72 ALS/FTD Martin H Schludi Martin H Schludi German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Search for more papers by this author Dieter Edbauer Dieter Edbauer [email protected] orcid.org/0000-0002-7186-4653 German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Search for more papers by this author Martin H Schludi Martin H Schludi German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Search for more papers by this author Dieter Edbauer Dieter Edbauer [email protected] orcid.org/0000-0002-7186-4653 German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany Search for more papers by this author Author Information Martin H Schludi1,2 and Dieter Edbauer1,2 1German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, Germany 2Munich Cluster for Systems Neurology (SyNergy), Munich, Germany EMBO Mol Med (2018)10:4-6https://doi.org/10.15252/emmm.201708572 See also: R Simone et al (January 2018) PDFDownload PDF of article text and main figures. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info The recent discovery of a pathogenic expansion of a (GGGGCC)n repeat in the C9orf72 gene in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) led to a burst of mechanistic discoveries. In this issue, Simone et al (2018) describe novel compounds targeting the G-quadruplex (G-Q) structure of the (GGGGCC)n repeat RNA that alleviate the hallmarks of C9orf72 disease in patient-derived neurons and increase survival in a Drosophila model. Lack of overt off-target effects and toxicity suggest that these small molecules are promising lead compounds to the development of a therapy. Since the discovery of the (GGGGCC)n repeat expansion upstream of the coding region of C9orf72 as the most common genetic cause of ALS and FTD, tremendous progress toward understanding disease mechanisms and developing therapies has been made (Edbauer & Haass, 2016). The repeat RNA forms small foci within the nucleus and is thought to sequester several RNA-binding proteins and thereby alter gene expression and splicing. Surprisingly, both sense and antisense transcripts are translated in all reading frames by an unconventional mechanism into five co-aggregating dipeptide repeat (DPR) proteins: poly-GA, poly-GP, poly-GR, poly-PA, and poly-PR. The DPRs also bind key cellular proteins (including RNA-binding proteins), and their relative role in pathogenesis is under intense investigation. The so-called repeat-associated non-ATG (RAN) translation has been first discovered for (CAG)n expansion disorders (Zu et al, 2011) and was later reported for several other repeat expansions diseases (Cleary & Ranum, 2017). The mechanism remains elusive, but seems to depend on the secondary structure of the repeat RNA. Therefore, several groups have analyzed the RNA structure of (GGGGCC)n repeats in vitro and in vivo and found that the repeat RNA can form both so-called G-quadruplexes (G-Qs) and hairpins. G-Qs are four-stranded structures containing stacks of four guanines that associate through Hoogsteen hydrogen bonding within one plane (Fig 1). This structure can form from a single or up to four separate RNA or DNA strands. In contrast to G-Qs formed from DNA, RNA-based G-Qs are more stable and compact as a consequence of more intramolecular interactions. Moreover, RNA G-Qs preferentially assemble in a parallel conformation. Thus, DNA and RNA G-Qs can be selectively targeted. Endogenous RNA G-Qs within untranslated regions and introns regulate transcription, alternative splicing, and protein binding. Hairpins composed of a base-paired stem and a loop are the most common RNA structures and can also affect transcription and alternative splicing. Thus, targeting the secondary structure of the disease-associated (GGGGCC)n RNA is a potential therapeutic strategy. Figure 1. Small molecules stabilize the GGGGCC RNA G-quadruplex structureSmall aromatic compounds with two amidine residues preferentially interact with the parallel G-Q of the (GGGGCC)n repeat RNA and stabilize this structure. Stabilization of the G-quadruplex structure reduces RNA foci formation and inhibits repeat translation. Note that other G-Q confirmations are possible. Download figure Download PowerPoint In 2014, Su et al repurposed a compound originally identified as an interactor of (CGG)n in fragile X-associated tremor ataxia syndrome for the C9orf72 repeat RNA (Su et al, 2014). This study describes in total three compounds (1a, 2, 3), which interfere mainly with the hairpin structure of the (GGGGCC)n RNA resulting in translational inhibition. In patient-derived neurons, compound 1a significantly reduced RNA foci and DPR proteins and showed no overt toxicity, but their more potent compound 2, an aromatic diamidine, was too toxic to validate in patient-derived neurons. None of the compounds were tested in animals. In contrast, Simone et al (2018) specifically targeted the G-Q structure and screened a library of 138 small molecules with known or suspected binding to G-Q structures (Fig 1). They used a FRET-based melting assay for the initial screen and selected three compounds that had a much larger effect on the G-Q formation of (GGGGCC)n RNA than of (GGGGCC)n DNA. The three best compounds have a nearly identical atomic structure and are, like the most potent compound in Su et al, aromatic diamidines. Circular dichroism spectroscopy confirms direct binding to repeat RNA with 200–400 nM affinity. At 1 μM concentration, two of the compounds reduced RNA foci in iPSC-derived spinal motor neurons and cortical neurons by about 50%. At higher concentration (16 μM) and later time points, both compounds also reduced poly-GP expression by up to 50%, which is likely due to the long half-life time of poly-GP. In contrast to the aromatic diamidine compound from Su et al, no toxicity was observed at the effective concentration. In addition to these biochemical and cellular assays, Simone et al (2018) fed their best compound (DB1273) to flies modeling (GGGGCC)n repeat toxicity (Mizielinska et al, 2014). Adult flies expressing (GGGGCC)36 showed a pronounced reduction in poly-GP. Moreover, feeding larvae with the compound led to a modest increase in survival. Since poly-GR is the main driver of toxicity in this model, Simone et al (2018) also developed a new poly-GR immunoassay to directly show effect on the main toxic species. Indeed, stabilizing the G-Q structure of (GGGGCC)36 using DB1273 also reduced poly-GR levels by 33%, which is consistent with the moderate survival benefit. Since brain penetrance of DB1273 is still low, medicinal chemists may be able to improve the in vivo effects significantly in the future. The Isaacs laboratory is covering a lot of ground already by validating their novel compounds in a fly model. The next obvious step would be treating mice expressing the (GGGGCC)n repeat. One strategy to improve delivery to the CNS might be biopharmaceutical modifications such as incorporation into nanospheres or nanocapsules (Lu et al, 2014). Another way to boost the efficiency of the compounds could be in situ CLICK chemistry, because 1,3-dipolar cycloaddition of alkynes and azides could promote cross-linking of the modified compounds to (GGGGCC)n G-Qs in vivo (Di Antonio et al, 2012). The report from Simone et al (2018) also highlights a gradual shift in the drug discovery world. In 2017, targeting specific RNA molecules by small molecules is becoming increasingly feasible (Bernat & Disney, 2015), although antisense oligonucleotides still have superior efficacy. However, antisense oligonucleotides require invasive application and come with a hefty price tag (Jiang et al, 2016). What do these new findings mean for our understanding of the pathological hallmarks of C9orf72 disease? Apparently, stabilizing either the G-Q or the hairpin structure can reduce RNA foci formation and inhibit translation of the (GGGGCC)n repeat. However, it is unclear whether the compounds actually dissolve RNA foci or just impair their detection. It also remains elusive whether these compounds specifically inhibit RAN translation or would also inhibit ATG-initiated translation of the structured repetitive RNA. RAN translation seems to highly depend on the RNA structure, because only (CAG)n but not (CAA)n repeats are translated into poly-Q in the absence of an ATG-start codon (Zu et al, 2011), suggesting that targeting the secondary structure of RAN-translated repeat RNAs is a potential strategy to slow or stop disease progression. A compound affecting RAN translation of different repeat RNAs might be beneficial for many diseases (Cleary & Ranum, 2017). In conclusion, this paper is an encouraging and timely study, because our understanding of C9orf72 pathogenesis is growing rapidly and the first treatment options, such as antisense oligonucleotides are already on the horizon (Jiang et al, 2016). Patients can only benefit from the intense interest in the C9orf72 mutation as academia and industry race for a treatment. Acknowledgements We apologize for not citing all relevant original literature due to space constrains. D.E. received funding from the European Community's Health Seventh Framework Programme under grant agreement 617198 [DPR-MODELS]. References Bernat V, Disney MD (2015) RNA structures as mediators of neurological diseases and as drug targets. Neuron 87: 28–46CrossrefCASPubMedWeb of Science®Google Scholar Cleary JD, Ranum LP (2017) New developments in RAN translation: insights from multiple diseases. Curr Opin Genet Dev 44: 125–134CrossrefCASPubMedWeb of Science®Google Scholar Di Antonio M, Biffi G, Mariani A, Raiber EA, Rodriguez R, Balasubramanian S (2012) Selective RNA versus DNA G-quadruplex targeting by in situ click chemistry. Angew Chem Int Ed Engl 51: 11073–11078Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Edbauer D, Haass C (2016) An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Curr Opin Neurobiol 36: 99–106CrossrefCASPubMedWeb of Science®Google Scholar Jiang J, Zhu Q, Gendron TF, Saberi S, McAlonis-Downes M, Seelman A, Stauffer JE, Jafar-Nejad P, Drenner K, Schulte D et al (2016) Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 90: 535–550CrossrefCASPubMedWeb of Science®Google Scholar Lu CT, Zhao YZ, Wong HL, Cai J, Peng L, Tian XQ (2014) Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine 9: 2241–2257CrossrefPubMedWeb of Science®Google Scholar Mizielinska S, Gronke S, Niccoli T, Ridler CE, Clayton EL, Devoy A, Moens T, Norona FE, Woollacott IO, Pietrzyk J et al (2014) C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 345: 1192–1194CrossrefCASPubMedWeb of Science®Google Scholar Simone R, Balendra R, Moens TG, Preza E, Wilson KM, Heslegrave A, Woodling NS, Niccoli T, Gilbert-Jaramillo J, Abdelkarim S et al (2018) G-quadruplex-binding small molecules ameliorate C9orf72 FTD/ALS pathology in vitro and in vivo. EMBO Mol Med 10: 22–31Wiley Online LibraryCASPubMedWeb of Science®Google Scholar Su Z, Zhang Y, Gendron TF, Bauer PO, Chew J, Yang WY, Fostvedt E, Jansen-West K, Belzil VV, Desaro P et al (2014) Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron 83: 1043–1050CrossrefCASPubMedWeb of Science®Google Scholar Zu T, Gibbens B, Doty NS, Gomes-Pereira M, Huguet A, Stone MD, Margolis J, Peterson M, Markowski TW, Ingram MA et al (2011) Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci USA 108: 260–265CrossrefCASPubMedWeb of Science®Google Scholar Previous ArticleNext Article Read MoreAbout the coverClose modalView large imageVolume 10,Issue 1,January 2018Cover: “ Genomic structural variations lead to dysregulation of important coding and non‐coding RNA species in dilated cardiomyopathy” by Jan Haas, Stefan Mester, Andreas E Posch, Benjamin Meder and colleagues. In a multi‐omics analysis, structural variants in dilated cardiomyopathy patients have been detected that are associated with altered gene expression. Besides regulatory genomic elements, also non‐coding RNAs have been identified as possible new players in the molecular homeostasis in the heart. Cover concept by the authors. (Artistic rendition by Uta Mackensen) Volume 10Issue 11 January 2018In this issue FiguresReferencesRelatedDetailsLoading ...